Replies to post #23 on Alexion Pharmaceuticals, Inc. (ALXN)

[surf1944]

6:35AM Alexion Pharma beats by $0.01, reports revs in-line; raises FY10 EPS guidance to in-line with consensus and raises FY10 priduct sales guidance (ALXN) 51.12 : Reports Q2 (Jun) earnings of $0.39 per share, $0.01 better than the Thomson Reuters consensus of $0.38; revenues rose 36.3% year/year to $125.8 mln vs the $125.8 mln consensus. Co issues guidance for FY10, sees EPS of $1.63-1.68, up from $1.60-1.65, vs. $1.68 Thomson Reuters consensus; sees FY10 worldwide net product sales are expected to be within an upwardly revised range of $515-530 mln, up from $505-520 mln, may not be comparable to $528.78 mln Thomson Reuters consensus.